Related Experiment Video
Updated: Jan 18, 2026

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice
Published on: April 7, 2014
Characterization and Treatment Patterns of Peri/Menopausal and Postmenopausal Women with and Without Vasomotor
Lena Charafi1, Kristina Bolling1, Bridgette Kanz Schroader2
1Bayer HealthCare, Whippany, NJ, USA.
Introduction:
Vasomotor symptoms (VMS) are the most commonly reported menopausal symptoms and vary across race and ethnicity, with higher prevalence and duration among Black and Hispanic women. This study describes demographics/clinical characteristics and treatment patterns of peri/menopausal and postmenopausal women with symptomatic menopause/VMS and asymptomatic menopause in a commercial claims population.
Methods:
Data from Optum's deidentified Clinformatics Data Mart Database were obtained for peri/menopausal (aged 40-54 years) and postmenopausal (aged 55-64 years) women. VMS is not available directly in claims data and was proxied using symptomatic menopausal ICD-9/10 codes. In Phase 1, prevalence of symptomatic and asymptomatic peri/menopause (defined by ICD-9/10 codes) and baseline demographics/clinical characteristics were obtained. Phase 2 included baseline demographics/clinical characteristics, symptomatic menopause/VMS incidence rates, and treatment patterns.
Results:
Phase 1 included 1,987,355 ICD-9/10 codes for symptomatic or asymptomatic menopause. Peri/menopausal women had lower symptomatic menopause/VMS prevalence compared to postmenopausal women (6.5% vs. 4.9%). Symptomatic menopause/VMS prevalence was 5.7% and highest in White (6.3%) and lowest in Asian (3.4%) women.Phase 2 included 203,546 (53.3%) peri/menopausal and 178,658 (46.7%) postmenopausal women. Symptomatic menopause/VMS incidence was 1.2%; only 52.9% were treated. Lower incidence and treatment rates were seen among Asian (0.46%; 33.2%), Hispanic (0.43%; 46.7%), and Black (0.41%; 47.1%) women compared to White (0.59%; 55.5%) women.
Conclusions:
This study adds to the literature by characterizing women with symptomatic menopause/VMS across the menopausal spectrum and shows that caution is needed when interpreting real-world claims data due to inherent claims database limitations. As there are no specific ICD codes for VMS, difficulties exist in utilization of claims data to accurately capture VMS characteristics and treatment patterns.
More Related Videos
06:18An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
07:20Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
Related Concept Videos
Menopause
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Disorders of the Female Reproductive System
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Hypertension III: Clinical Manifestations and Diagnostic Studies